Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.

Abstract: A system for communicating between blockchains on heterogeneous blockchain networks. The system can include a sending blockchain configured to transmit a first message via a sending blockchain protocol, wherein the sending blockchain forms a part of a sending blockchain network. The system can include a sending adapter node configured to receive the first message from the sending blockchain and translate the first message from the sending blockchain protocol to an adapter protocol. The system can include a receiving adapter node configured to receive the first message from the sending adapter node and translate the first message from the adapter protocol to a receiving blockchain protocol. The system can include a receiving blockchain configured to receive the first message from the receiving adapter node, and validate the first message, wherein the receiving blockchain forms a part of a receiving blockchain network.

Abstract: The subject technology receives, from a document object model, a set of nodes of a web page, each node corresponding to an element of the web page. The subject technology determines, using an intersection observer, a position and visibility of a set of first elements within a viewport of the web page. The subject technology determines, using a mutation observer, a set of new elements within the viewport that was previously hidden and now visible. The subject technology provides a set of visible elements, based at least in part on the set of new elements and the set of first element, as elements that have been seen by a user during a session. The subject technology generates an index based at least in part on the set of visible elements, the index comprising information corresponding to text that was visible to the user during the session.

Abstract: A method of selectively locking a cryptographic digital asset includes instructing or requesting the creation or minting of a plurality of cryptographic tokens via a first common digital contract registered to a distributed ledger. Each cryptographic token is a digital asset that includes at least one attribute that is operative to evolve or change through a plurality of evolutionary stages. The plurality of cryptographic tokens are then instructed to be transferred to a plurality of token holders. The method further includes receiving a request from a token holder to selectively lock their digital asset at one of the plurality of evolutionary stages; and instructing or requesting the transfer of a second cryptographic token to the token holder, the second cryptographic token having at least one attribute that is at least partially derived from the evolutionary stage of the digital asset at the time of the request.

Abstract: The present disclosure relates to compositions and methods for treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be provided in an artificial cerebrospinal fluid. About 1 mg to about 100 mg of the recombinant polypeptide may be administered to the patient once every 2 weeks to 6 months.

Abstract: The present disclosure relates to compositions and methods for treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be provided in an artificial cerebrospinal fluid. About 1 mg to about 100 mg of the recombinant polypeptide may be administered to the patient once every 2 weeks to 6 months.

Abstract: The present compositions and methods relate to a beta-mannanase from Bacillus hemicellulosilyticus, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Bacillus hemicellulosilyticus, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Actinosynnema mirum, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Paenibacillus pabuli, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Paenibacillus macerans, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Paenibacillus polymyxa, polynucleotides encoding the beta-mannanase, and methods of making and/or using thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Mahella australiensis, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Streptococcus gallolyticus, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Paenibacillus kribbensis, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Bacillus hemicellulosilyticus, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Thermobifida fusca, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present compositions and methods relate to a beta-mannanase from Bacillus licheniformis, polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Abstract: The present disclosure provides methods and compositions for reducing the viscosity of biomass process streams in an ethanol production process. The method comprises adding cellulase enzymes to a biomass feedstock that is fermented to produce ethanol, generating whole stillage and thin stillage streams from the post-fermentation biomass, and adding an additional enzyme or enzyme cocktail that reduces the viscosity of the whole stillage stream, thin stillage stream, concentrated thin stillage stream, and/or the syrup stream generated by evaporating the thin stillage.

Abstract: A closure device for a fluid vessel can comprise a bistable valve arrangement which includes first and second valve rim portions and a valve member engageable with either of the rim portions respectively to define an open position in which fluid can exit the vessel and a closed position in which fluid is substantially prevented from exiting the vessel The valve can be arranged to close automatically when an impulse is exerted against the valve member. This can occur for example when the vessel is knocked over and the fluid therein exerts pressure against the valve member.